TOP TEN perturbations for 39254_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39254_at
Selected probe(set): 202052_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39254_at (202052_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.181844Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
oxyphilic adenoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-3.7018185Number of Samples:4 / 2
| Experimental | oxyphilic adenoma study 1 |
| Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.6748219Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM2) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
monocyte activation study 1 (NOD2L; 24h) / untreated monocyte sample (24h)
Relative Expression (log2-ratio):3.5455256Number of Samples:5 / 5
| Experimental | monocyte activation study 1 (NOD2L; 24h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells. | |
| Control | untreated monocyte sample (24h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 24 hours for RNA isolation. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):3.532692Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):-3.51764Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
myotonic dystrophy study 4 (deltoid muscle; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.5076094Number of Samples:2 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM1) |
| Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.4830666Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.4298286Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM2) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-3.4199305Number of Samples:9 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM-like) |
| Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |